Department of Psychiatry, Indiana University School of Medicine, 702 Barnhill Drive, Room 4300, Indianapolis, IN 46202, USA.
J Autism Dev Disord. 2009 Dec;39(12):1629-35. doi: 10.1007/s10803-009-0807-3. Epub 2009 Jul 16.
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.
谷氨酸能功能障碍与脆性 X 综合征（FXS）的病理生理学有关。本初步研究旨在研究美金刚治疗与 FXS 相关的多种目标症状的有效性和耐受性。对描述 6 例 FXS 合并 PDD 共病诊断患者接受美金刚开放标签治疗的医疗记录进行了回顾。6 例患者平均接受美金刚治疗 34.7 周。6 例患者中有 4 例（67%）在 CGI-I 评定中表现出总体临床获益。然而，症状特异性评定量表没有显示出统计学上的显著改善。两名患者在使用美金刚时出现了治疗限制的激惹。美金刚在数名 FXS 患者中具有一定疗效。需要进一步的系统研究。
